Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer

Cancer Biology and Therapy

Volumn 18, Issue 8, 2017, Pages 627-634

  Ma, Ruishuang ^a   Bi, Yayan ^a   Kou, Junjie ^a   Zhou, Jin ^a   Shi, Jialan ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; non small cell lung cancer; platelet; procoagulant activity; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CISPLATIN; D DIMER; FIBRIN; GEMCITABINE; LACTADHERIN; PHOSPHATIDYLSERINE; PROCOAGULANT; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; ANTITHROMBOCYTIC AGENT; MEMBRANE ANTIGEN; MFGE8 PROTEIN, HUMAN; MILK PROTEIN; THROMBOPLASTIN;

AGED; APOPTOSIS; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FIBRIN FORMATION; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; IN VITRO STUDY; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PARTIAL THROMBOPLASTIN TIME; PLATELET MICROPARTICLE; PROTHROMBIN TIME; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TUMOR THROMBUS; UPREGULATION; BLEEDING TIME; BLOOD; DRUG EFFECT; LUNG TUMOR; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; THROMBOSIS;

AGED; ANTIGENS, SURFACE; ASPIRIN; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; CELL-DERIVED MICROPARTICLES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MILK PROTEINS; PHOSPHATIDYLSERINES; PLATELET AGGREGATION INHIBITORS; THROMBIN; THROMBOPLASTIN; THROMBOSIS; UP-REGULATION;

EID: 85029704837     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2017.1345387     Document Type: Article

References (31)

1. Walker AJ, Baldwin DR, Card TR, Powell HA, Hubbard RB, Grainge MJ. Risk of venous thromboembolism in people with lung cancer: A cohort study using linked UK healthcare data. Br J Cancer 2016; 115(1):115-21; PMID:27253177; https://doi.org/10.1038/bjc.2016.143
2. Jara-Palomares L, Otero R, Jimenez D, Carrier M, Tzoran I, Brenner B, Margeli M, Praena-Fernandez JM, Grandone E, Monreal M, et al. Development of a risk prediction score for occult cancer in patients with venous thromboembolism. Chest 2017 Nov 1. pii: S0012-3692(16)62282-1; 151(3):564-71; PMID:27815153; https://doi.org/10.1016/j.chest.2016.10.025
3. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 2014; 8:129-37; PMID:25520567; https://doi.org/10.4137/CMO.S18991
4. Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, Leighl NB, et al. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer. 2017; 18(2):156-61;PMID:27913214; https://doi.org/10.1016/j.cllc.2016.10.007
5. Li R, Hermann G, Baldini E, Chen A, Jackman D, Kozono D, Nguyen P, Nohria A, Powell G, Mak R. Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer. Lung Cancer 2016; 96:41-7; PMID:27133748; https://doi.org/10.1016/j.lungcan.2016.03.004
6. Nadir Y, Brenner B. Heparanase procoagulant activity in cancer progression. Thromb Res 2016; 140(Suppl 1):S44-8; PMID:27067977; https://doi.org/10.1016/S0049-3848(16)30097-4
7. Nadir Y, Sarig G, Axelman E, Meir A, Wollner M, Shafat I, Hoffman R, Brenner B, Vlodavsky I, Haim N. Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients. Thromb Res 2014; 134(3):639-42; PMID:25065557; https://doi.org/10.1016/j.thromres.2014.07.006
8. Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. Clin Lung Cancer 2008; 9(2):112-5; PMID:18501098; https://doi.org/10.3816/CLC.2008.n.017
9. Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y, Mishima M. Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. Med Oncol 2011; 28(1):351-6; PMID:20300980; https://doi.org/10.1007/s12032-010-9454-y
10. Kim S-H, Lee HW, Go S-I, Lee SI, Lee G-W. Clinical signifiance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget 2016; 7(24):36198-206; PMID:27105529; https://doi.org/10.18632/oncotarget.8809
11. Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, Menekse S, Kocar M, Sen CA, Ordu C, et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J 2016 Dec 27; PMID:28026133; https://doi.org/10.1111/crj.12605
12. Fu Y, Zhou J, Li H, Cao F, Su Y, Fan S, Li Y, Wang S, Li L, Gilbert GE, et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost 2010; 104(6):1235-41; PMID:20886178; https://doi.org/10.1160/TH10-02-0102
13. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, et al. NCCN guidelines insights: Non-small cell lung cancer, Version 4.2016. J Natl Compr Canc Netw 2016; 14(3):255-64; PMID:26957612; https://doi.org/10.6004/jnccn.2016.0031
14. Ding W, Kou J, Shi J, Kou Y, He Z, Cao M, Wang L, Bi Y, Thatte HS, Shi J. Procoagulant activity induced by transcatheter closure of atrial septal defects is associated with exposure of phosphatidylserine on microparticles, platelets and red blood cells. Thromb Res 2015; 136(2):354-60; PMID:26099643; https://doi.org/10.1016/j.thromres.2015.06.015
15. Wang L, Bi Y, Shi J, Ma R, Wu X, Zhang Y, Ding W, Liu Y, Yu Q, Zhang Y, et al. Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation. Int J Cardiol 2016; 223:121-8; PMID:27537737; https://doi.org/10.1016/j.ijcard.2016.07.260
16. Yao Z, Wang L, Shi J, Zhao L, Chi C, Guo L, Tong D, Yang X, Dong Z, Deng R, et al. Enhanced procoagulant activity on blood cells after acute ischemic stroke. Transl Stroke Res 2017; 8(1):83-91; PMID:27650774; https://doi.org/10.1007/s12975-016-0501-7
17. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114(23):4886-96; PMID:19797520; https://doi.org/10.1182/blood-2009-06-228940
18. Kee NLA, Krause J, Blatch GL, Muramoto K, Sakka K, Sakka M, Naudé RJ, Wagner L, Wolf R, Rahfeld JU, et al. The Proteolytic Profile of Human Cancer Procoagulant Suggests That It Promotes Cancer Metastasis at the Level of Activation Rather Than Degradation. Protein J 2015; 34(5):338-48; PMID:26341972; https://doi.org/10.1007/s10930-015-9628-8
19. Lysov Z, Swystun LL, Kuruvilla S, Arnold A, Liaw PC. Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. Blood Coagul Fibrinolysis 2015; 26(1):36-45; PMID:24911456; https://doi.org/10.1097/MBC.0000000000000145
20. Gay LJ, Felding-Habermann B. Contribution of platelets to tumourmetastasis. Nat Rev Cancer 2011; 11(2):123-34; PMID:21258396; https://doi.org/10.1038/nrc3004
21. Vitale C, D'Amato M, Calabrò P, Stanziola AA, Mormile M, Molino A. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med 2015; 10(1):28; PMID:26380084; https://doi.org/10.1186/s40248-015-0021-4
22. Yang C, Shi J, Zou X, Cao M, Zhao L, Bi Y, Kou J, Shi J, Zou X. Contributions of phosphatidylserine-positive platelets and leukocytes and microparticles to hypercoagulable state in gastric cancer patients. Tumour Biol 2016; 37(6):7881-91; PMID:26700666; https://doi.org/10.1007/s13277-015-4667-5
23. Zhao L, Bi Y, Kou J, Shi J, Piao D. Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. J Exp Clin Cancer Res 2016; 35:54; PMID:27015840; https://doi.org/10.1186/s13046-016-0328-9
24. Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: A comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther 2016; 5(1):1-18; PMID:26935434; https://doi.org/10.1007/s40119-016-0058-2
25. Hoffan EA, Gizelska K, Mirowski M, Mielicki W. Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro. Contemp Oncol (Pozn) 2015; 19(2):108-12; PMID:26034387; https://doi.org/10.5114/wo.2014.41390
26. Zhou J, Shi J, Hou J, Cao F, Zhang Y, Rasmussen JT, Heegaard CW, Gilbert GE. Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost 2010; 8(4):773-82; PMID:20102487; https://doi.org/10.1111/j.1538-7836.2010.03763.x
27. Zubairova LD, Nabiullina RM, Nagaswami C, Zuev YF, Mustafin IG, Litvinov RI, Weisel JW. Circulating microparticles alter formation, structure, and properties of fibrin clots. Sci Rep 2015; 5:17611; PMID:26635081; https://doi.org/10.1038/srep17611
28. van Doormaal F, Kleinjan A, Berckmans RJ, Mackman N, Manly D, Kamphuisen PW, Richel DJ, Büller HR, Sturk A, Nieuwland R. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108(1):160-5; PMID:22535219; https://doi.org/10.1160/TH12-02-0099
29. Chen W, Zhang Y, Yang Y, Zhai Z, Wang C. Prognostic significance of arterial and venous thrombosis in resected specimens for non-small cell lung cancer. Thromb Res 2015; 136(2):451-5; PMID:26099644; https://doi.org/10.1016/j.thromres.2015.06.014
30. Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer 2014; 86(3):358-62; PMID:25453848; https://doi.org/10.1016/j.lungcan.2014.10.003
31. Gao C, Xie R, Yu C, Wang Q, Shi F, Yao C, Xie R, Zhou J, Gilbert GE, Shi J. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost 2012; 107(4):681-9; PMID:22370875; https://doi.org/10.1160/TH11-09-0673